✦ LIBER ✦

Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment

✍ Scribed by A. D. Anastasilakis, S. A. Polyzos, P. Makras, A. Gkiomisi…

Book ID: 120745743
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 153 KB
Volume: 24
Category: Article
ISSN: 0937-941X
DOI: 10.1007/s00198-012-2198-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rapid Onset and Sustained Efficacy (ROSE

Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass

✍ P. Hadji; D. Gamerdinger; W. Spieler; P. H. Kann; H. Loeffler; K. Articus; R. Mö 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 228 KB

Odanacatib in the treatment of postmenop

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

✍ John A Eisman; Henry G Bone; David J Hosking; Michael R McClung; Ian R Reid; Ren 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 211 KB 👁 2 views

## Abstract The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral density (BMD) and decreased bone‐resorption markers during 2 years of treatment in postmenopausal women with low BMD. A 1‐year extension study further assessed ODN efficacy and safety and the effec

Quality of life and health status with z

Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass

✍ P. Hadji, V. Ziller, D. Gamerdinger, W. Spieler, K. Articus, M. Baier, R. Moeric 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 176 KB

P154 Twenty-four month follow-up of the

P154 Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

✍ A. Brufsky; K. Lund; S. Papish; P. Cobb; P. Eisenberg; M. Dong; G. Warsi; L. Lac 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB